Rab Prinjha leads the Adaptive Immunity and Immuno-Epigenetics Research Unit and cofounded the GSK Biology Council and is an elected fellow of the Academy of Medical Sciences and the Royal Society of Biology. He represented GSK on the EU-EFPIA Board through which he chaired the Immunology SGG. He currently chairs the Open Targets Governance Board. He served as a member of the Padlock Board of Directors until its acquisition by BMS in 2016. He has recently been appointed to the UK MRC PSMB Board and is on the SAB of the MRC UK Human Genetics Unit. He is a co-founder and board member of the Milner Therapeutics Consortium and is co-leading the H2020 Epimac collaboration.
Previously, under his leadership the GSK Epigenetics DPU was responsible for many novel and exciting discoveries in the area of exploring and exploiting epigenetic inhibitors in human disease treatment. His group has already advanced seven novel epigenetic medicines into clinical studies with many more in the pipeline and has collaborated with many world leading labs leading to an extensive high impact publication record. Rab joined GSK from academia including a post-doc in developmental neuroscience at Guy’s Hospital and PhD in molecular cellular immunology at UCL after a degree in Biotechnology at King’s College London.
